Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 10, 2012 - Issue 9
Submit an article Journal homepage
60
Views
4
CrossRef citations to date
0
Altmetric
Theme: Heart Failure - Review

Reassessing the use of vasodilators in heart failure

Robert T Cole Emory University, Atlanta, GA 30322, USA; Emory University, Atlanta, GA 30322, USA. [email protected]
,
Mihai Gheorghiade Northwestern University, Chicago, IL, USA; Northwestern University, Chicago, IL, USA
,
Vasiliki V Georgiopoulou Emory University, Atlanta, GA 30322, USA; Emory University, Atlanta, GA 30322, USA
,
Divya Gupta Emory University, Atlanta, GA 30322, USA; Emory University, Atlanta, GA 30322, USA
,
Catherine N Marti Emory University, Atlanta, GA 30322, USA; Emory University, Atlanta, GA 30322, USA
,
Andreas P Kalogeropoulos Emory University, Atlanta, GA 30322, USA; Emory University, Atlanta, GA 30322, USA
&
Javed Butler Emory University, Atlanta, GA 30322, USA; Emory University, Atlanta, GA 30322, USA
 show all
Pages 1141-1151 | Published online: 10 Jan 2014

References

  • Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics – 2011 update: a report from the american heart association. Circulation 1c23, e18–e209 (2011).
  • Rose EA, Gelijns AC, Moskowitz AJ et al. ; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N. Engl. J. Med. 345(20), 1435–1443 (2001).
  • Imperial ES, Levy MN, Zieske H. Outflow resistance as an independent determinant of cardiac performance. Circ. Res. 9, 1148–1155 (1961).
  • Sonnenblick EH, Downing SE. Afterload as a primary determinat of ventricular performance. Am. J. Physiol. 204, 604–610 (1963).
  • Franciosa JA, Cohn JN. Effects of minoxidil on hemodynamics in patients with congestive heart failure. Circulation 63(3), 652–657 (1981).
  • Franciosa JA, Limas CJ, Guiha NH, Rodriguera E, Cohn JN. Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet 1(7752), 650–654 (1972).
  • Franciosa JA, Mikulic E, Cohn JN, Jose E, Fabie A. Hemodynamic effects of orally administered isosorbide dinitrate in patients with congestive heart failure. Circulation 50(5), 1020–1024 (1974).
  • Franciosa JA, Pierpont G, Cohn JN. Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients. Ann. Intern. Med. 86(4), 388–393 (1977).
  • Guiha NH, Cohn JN, Mikulic E, Franciosa JA, Limas CJ. Treatment of refractory heart failure with infusion of nitroprusside. N. Engl. J. Med. 291(12), 587–592 (1974).
  • Miller RR, Awan NA, Maxwell KS, Mason DT. Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. N. Engl. J. Med. 297(6), 303–307 (1977).
  • Schreiber R, Maier PT, Gunnar RM, Loeb HS. Hemodynamic improvement following a single dose of oral phentolamine. Administration in patients with chronic low output cardiac failure. Chest 76(5), 571–575 (1979).
  • Massie B, Chatterjee K, Werner J, Greenberg B, Hart R, Parmley WW. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure. Am. J. Cardiol. 40(5), 794–801 (1977).
  • Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med. 314(24), 1547–1552 (1986).
  • Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325(5), 303–310 (1991).
  • Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator–Heart Failure Trial Study Group. J. Card. Fail. 5(3), 178–187 (1999).
  • Taylor AL, Ziesche S, Yancy C et al. ; African American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 351(20), 2049–2057 (2004).
  • Cardillo C, Kilcoyne CM, Cannon RO 3rd, Panza JA. Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation 99(1), 90–95 (1999).
  • Cole RT, Kalogeropoulos AP, Georgiopoulou VV et al. Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions. Circulation 123(21), 2414–2422 (2011).
  • Stein CM, Lang CC, Nelson R, Brown M, Wood AJ. Vasodilation in black Americans: attenuated nitric oxide-mediated responses. Clin. Pharmacol. Ther. 62(4), 436–443 (1997).
  • Vita JA. Nitric oxide and vascular reactivity in African American patients with hypertension. J. Card. Fail. 9(Suppl. 5), S199–S204; discussion S205 (2003).
  • Daiber A, Oelze M, Coldewey M et al. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem. Biophys. Res. Commun. 338(4), 1865–1874 (2005).
  • Münzel T, Daiber A, Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 123(19), 2132–2144 (2011).
  • Münzel T, Kurz S, Rajagopalan S et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J. Clin. Invest. 98(6), 1465–1470 (1996).
  • Hare JM. Nitroso–redox balance in the cardiovascular system. N. Engl. J. Med. 351(20), 2112–2114 (2004).
  • The consensus trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian enalapril survival study (consensus). N. Engl. J. Med. 316, 1429–1435 (1987).
  • The solvd investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293–302 (1991).
  • The acute infarction ramipril efficacy (aire) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342, 821–828 (1993).
  • Braunwald E. ACE inhibitors – a cornerstone of the treatment of heart failure. N. Engl. J. Med. 325(5), 351–353 (1991).
  • Køber L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med. 333(25), 1670–1676 (1995).
  • Rydén L, Armstrong PW, Cleland JG et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur. Heart J. 21(23), 1967–1978 (2000).
  • Stevenson LW, Tillisch JH. Maintenance of cardiac output with normal filling pressures in patients with dilated heart failure. Circulation 74(6), 1303–1308 (1986).
  • Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 51(5), 831–836 (1983).
  • Unverferth DV, Magorien RD, Moeschberger ML, Baker PB, Fetters JK, Leier CV. Factors influencing the one-year mortality of dilated cardiomyopathy. Am. J. Cardiol. 54(1), 147–152 (1984).
  • Johnson W, Omland T, Hall C et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J. Am. Coll. Cardiol. 39(10), 1623–1629 (2002).
  • Stevenson LW, Sietsema K, Tillisch JH et al. Exercise capacity for survivors of cardiac transplantation or sustained medical therapy for stable heart failure. Circulation 81(1), 78–85 (1990).
  • Stevenson LW, Steimle AE, Fonarow G et al. Improvement in exercise capacity of candidates awaiting heart transplantation. J. Am. Coll. Cardiol. 25(1), 163–170 (1995).
  • Hamilton MA, Stevenson LW, Child JS, Moriguchi JD, Walden J, Woo M. Sustained reduction in valvular regurgitation and atrial volumes with tailored vasodilator therapy in advanced congestive heart failure secondary to dilated (ischemic or idiopathic) cardiomyopathy. Am. J. Cardiol. 67(4), 259–263 (1991).
  • Rosario LB, Stevenson LW, Solomon SD, Lee RT, Reimold SC. The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size. J. Am. Coll. Cardiol. 32(7), 1819–1824 (1998).
  • Stevenson LW, Dracup KA, Tillisch JH. Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation. Am. J. Cardiol. 63(7), 461–464 (1989).
  • Steimle AE, Stevenson LW, Chelimsky-Fallick C et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation 96(4), 1165–1172 (1997).
  • Stevenson LW, Tillisch JH, Hamilton M et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am. J. Cardiol. 66(19), 1348–1354 (1990).
  • Massie BM, Kramer BL, Topic N. Lack of relationship between the short-term hemodynamic effects of captopril and subsequent clinical responses. Circulation 69(6), 1135–1141 (1984).
  • Walsh WF, Greenberg BH. Results of long-term vasodilator therapy in patients with refractory congestive heart failure. Circulation 64(3), 499–505 (1981).
  • Franciosa JA, Goldsmith SR, Cohn JN. Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am. J. Med. 69(4), 559–566 (1980).
  • Levine TB, Franciosa JA, Cohn JN. Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation 62(1), 35–41 (1980).
  • Massie B, Ports T, Chatterjee K et al. Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements. Circulation 63(2), 269–278 (1981).
  • Massie BM, Kramer B, Haughom F. Acute and long-term effects of vasodilator therapy on resting and exercise hemodynamics and exercise tolerance. Circulation 64(6), 1218–1226 (1981).
  • Packer M, Meller J, Gorlin R, Herman MV. Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation 59(3), 531–539 (1979).
  • Binanay C, Califf RM, Hasselblad V et al. ; ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294(13), 1625–1633 (2005).
  • Allhat Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (allhat). JAMA 283, 1967–1975 (2000).
  • Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287, 1531–1540 (2002).
  • Mentzer RM Jr, Oz MC, Sladen RN et al. ; NAPA Investigators. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J. Am. Coll. Cardiol. 49(6), 716–726 (2007).
  • Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111(12), 1487–1491 (2005).
  • Aaronson KD, Sackner-Bernstein J. Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA 296(12), 1465–1466 (2006).
  • Arora RR, Venkatesh PK, Molnar J. Short and long-term mortality with nesiritide. Am. Heart J. 152(6), 1084–1090 (2006).
  • Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293(15), 1900–1905 (2005).
  • O’Connor CM, Starling RC, Hernandez AF et al. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 365(1), 32–43 (2011).
  • Califf RM, Adams KF, McKenna WJ et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am. Heart J. 134(1), 44–54 (1997).
  • Moe GW, Rouleau JL, Charbonneau L et al. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan. Am. Heart J. 139(4), 587–595 (2000).
  • Packer M, O’Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N. Engl. J. Med. 335(15), 1107–1114 (1996).
  • Cohn JN, Ziesche S, Smith R et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 96(3), 856–863 (1997).
  • McMurray JJ, Teerlink JR, Cotter G et al. ; VERITAS Investigators. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298(17), 2009–2019 (2007).
  • Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J. Am. Coll. Cardiol. 59(5), 442–451 (2012).
  • Cuffe MS, Califf RM, Adams KF Jr et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287(12), 1541–1547 (2002).
  • Felker GM, Benza RL, Chandler AB et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J. Am. Coll. Cardiol. 41(6), 997–1003 (2003).
  • Izzo JL Jr, Licht MR, Smith RJ, Larrabee PS, Radke KJ, Kallay MC. Chronic effects of direct vasodilation (pinacidil), α-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension. Am. J. Cardiol. 60(4), 303–308 (1987).
  • Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N. Engl. J. Med. 327(10), 678–684 (1992).
  • Markham RV Jr, Corbett JR, Gilmore A, Pettinger WA, Firth BG. Efficacy of prazosin in the management of chronic congestive heart failure: a 6-month randomized, double-blind, placebo-controlled study. Am. J. Cardiol. 51(8), 1346–1352 (1983).
  • Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 82(6), 1954–1961 (1990).
  • >Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II – DAVIT II). Am. J. Cardiol. 66, 779–785 (1990).
  • Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 83(1), 52–60 (1991).
  • Packer M. Results from late-breaking clinical trials sessions: Praise-2. J. Am. Coll. Cardiol. 36, 255–261 (2000).
  • Packer M, McMurray J, Massie BM et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J. Card. Fail. 11(1), 12–20 (2005).
  • Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for nonselective endothelin antagonism in heart failure? Int. J. Cardiol. 85(2–3), 195–197 (2002).
  • Coletta AP, Cleland JG. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology – WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur. J. Heart Fail. 3(6), 747–750 (2001).
  • O’Connor CM, Gattis WA, Adams KF Jr et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J. Am. Coll. Cardiol. 41(9), 1452–1457 (2003).
  • Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 325(21), 1468–1475 (1991).
  • Uretsky BF, Jessup M, Konstam MA et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 82(3), 774–780 (1990).
  • Packer M, Rouleau JL, Swedberg K, Pitt B, Fisher L, Klepper M. Effect of flosequinan on survival in chronic heart failure: preliminary results of the profile study. Circulation 88(Suppl. 1), 301 (1993).
  • Franciosa JA, Jordan RA, Wilen MM, Leddy CL. Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial. Circulation 70(1), 63–68 (1984).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.